Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ADH1B | P00325 | 4/20 | 0.44 |
| ▸ | ADH1A | P07327 | 4/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.41 |
| ▸ | ADH1C | P00326 | 3/20 | 0.41 |
| ▸ | ADH7 | P40394 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | GRM7 | Q14831 | 3/20 | 0.40 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853529 | 0.86 | MTNR1A (0.56) | CA1CA2MTNR1AMTNR1BGRIN2B | |
| SCHEMBL8561460 | 0.78 | EPHX2 (0.52) | CA1CA2ADH1BADH1AMTNR1A | |
| SCHEMBL8561461 | 0.78 | EPHX2 (0.52) | CA1CA2ADH1BADH1AMTNR1A | |
| SCHEMBL8561458 | 0.78 | EPHX2 (0.52) | CA1CA2ADH1BADH1AMTNR1A | |
| SCHEMBL6589968 | 0.78 | CA1 (0.52) | CA1CA2MTNR1AMTNR1BGRIN2B | |
| SCHEMBL7349262 | 0.75 | MTNR1A (0.36) | CA1CA2ADH1BADH1AMTNR1A | |
| SCHEMBL9716425 | 0.73 | PNMT (0.50) | — | |
| SCHEMBL28143456 | 0.72 | PRCP (0.44) | — | |
| SCHEMBL433595 | 0.71 | GRIN2B (0.52) | CA1CA2MTNR1AMTNR1BGRIN2B | |
| SCHEMBL8613628 | 0.71 | GRIN2B (0.53) | CA1CA2MTNR1AMTNR1BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797820-B2 | HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS | VICURON PHARMACEUTICALS INC. | 2004-09-28 | — | — | US | claimed |
| EP-1237862-A1 | SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | Versicor, Inc. (US) | 2002-09-11 | — | — | EP | claimed |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | VICURON HOLDINGS LLC | 2002-08-22 | — | — | US | claimed |
| US-6380197-B1 | FOR TREATING AND PREVENTING A PLETHORA OF DISEASES INCLUDING DIABETES | AVENTIS PHARMA S. A. (FR) | 2002-04-30 | — | — | US | claimed |
| WO-2001044179-A1 | NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION | VERSICOR, INC. (US) | 2001-06-21 | — | — | WO | claimed |
| EP-1001943-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-05-24 | — | — | EP | claimed |
| WO-1999003843-A1 | POLYHYDROXYALKYLPYRAZINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1999-01-28 | — | — | WO | claimed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2021-12-16 | — | — | US | disclosed |
| CN-108558665-A | A kind of method that the catalysis of excited by visible light disulfide prepares Alpha-hydroxy-beta-dicarbonyl compound | 大连理工大学 | 2018-09-21 | — | — | CN | disclosed |
| WO-2018129393-A1 | MU OPIOID RECEPTOR MODULATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-07-12 | — | — | WO | disclosed |
| WO-2018047983-A1 | INDANE DERIVATIVES USEFUL AS MODULATORS OF MGLUR7 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-15 | — | — | WO | disclosed |
| EP-2091951-B1 | PYRIDO[2,3-B]PYRAZINE AND [1,8]-NAPHTHYRIDINE DERIVATIVES AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-5030652-A | Thromboxane A2 antagonists | TANABE SEIYAKU CO., LTD. (JP) | 1991-07-09 | — | — | US | disclosed |
| US-5006561-A | Indane sulfonamide anti-arrhythmic agents and use | PFIZER INC. (US) | 1991-04-09 | — | — | US | disclosed |
| EP-0286277-B1 | ANTIARRYTHMIC AGENTS | Pfizer Limited (GB) | 1990-06-20 | — | — | EP | disclosed |
| EP-0317321-A2 | Indan derivatives and process for preparation thereof | TANABE SEIYAKU CO., LTD. (JP) | 1989-05-24 | — | — | EP | disclosed |
| US-4829071-A | Quinolyl substituted indane sulfonamides and their use as anti-arrhythmic agents | PFIZER INC. (US) | 1989-05-09 | — | — | US | disclosed |
| EP-0286277-A1 | Antiarrythmic agents | Pfizer Limited (GB) | 1988-10-12 | — | — | EP | disclosed |
| EP-0286278-A1 | Indanamine derivatives useful as antiarrhythmic agents | Pfizer Limited (GB) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | CA1 1164/4885CA2 1117/4885ADH1B 1672/4885 |
| US-20210387986-A1 | INHIBITORS OF INTEGRIN ALPHA 2 BETA 1 AND METHODS OF USE | ITGB1, ITGB2, ITGA2 | CA1 1164/4885CA2 1117/4885ADH1B 1672/4885 |
| US-20020115863-A1 | Novel succinate compounds, compositions and methods of use and preparation | PDF, MMP2, SDHA | CA1 2797/4885CA2 2344/4885ADH1B 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.